Market Intelligence, Clinical Progress, and High-Purity Reagents for Dyslipidemia, Cardiovascular Disease, and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HMGCR drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HMGCR Catalytic Domain / Mutant Proteins. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Expressed in HEK293 or E.coli. Suitable for enzyme kinetics, inhibitor screening, and structure-activity relationship studies. | View HMGCR Products |
| Gene Delivery | HMGCR Lentivirus / Promise-ORF particles. Full-length ORF for stable HepG2, CHO, or other cell lines. Ideal for overexpression, PROTAC degradation assays, and native ER-membrane topology studies. Endotoxin controlled. | View HMGCR Products |
| Benchmark Ab | Anti-HMGCR Monoclonal Antibody. Recombinant positive control, sequence verified, suitable for Western blot, IP, and target engagement assays. | View HMGCR Products |
| Validator | HMGCR siRNA Set (3 unique sequences). For knockdown verification, specificity checks, and cholesterol synthesis assays. | View HMGCR Products |
| Related Target: PCSK9 | PCSK9. Complementary LDL-lowering pathway; critical for combination therapy studies. | View PCSK9 Products |
| Related Target: LDLR | LDLR. Downstream effector; essential for cholesterol uptake validation. | View LDLR Products |
| Related Target: ACLY | ACLY (ATP citrate lyase). Upstream metabolic enzyme; combined lipid-lowering efficacy (target of Bempedoic acid). | View ACLY Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzyme Activity & Statin Competition | High-purity Catalytic Domain (>95%) with theoretical MW verification; suitable for NADPH consumption assays and binding studies. |
| Cellular Cholesterol Synthesis Model | Lentivirus-delivered Full-length HMGCR for stable HepG2 lines; native ER membrane integration preserved; applicable for degradation and functional assays. |
| Statin Resistance Mutations | Mutant Recombinant Proteins (e.g., HMGCR variants) available for structure-activity relationship studies. |
| Cross-species Toxicology | Human/Mouse/Cyno ortholog proteins available with >95% purity for comparative pharmacology and toxicology. |
| Target Engagement for Degraders (PROTACs) | Lentivirus-mediated stable cell line generation preserves ER-membrane topology for accurate cellular assays measuring degradation kinetics. |
| Inhibitor Screening (Catalytic activity) | Soluble catalytic domain recombinant proteins with Sequence Verified, High Purity (>95%) profiles for biochemical screening. |
| Lack of Controls | Sequence-verified recombinant benchmark antibodies included as positive controls. |
| False Positives | Validated siRNA included for specificity and knockdown checks to confirm on-target effects. |
Live HMGCR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for next-generation HMGCR therapeutics is undergoing a renaissance. While statins remain the gold standard for hypercholesterolemia, the field is shifting beyond traditional small-molecule inhibition towards precision medicine approaches. Key trends include: (1) targeted protein degraders (PROTACs) to overcome statin intolerance and compensatory enzyme upregulation; (2) novel allosteric inhibitors with improved safety profiles; (3) combination therapies with PCSK9 inhibitors, ACLY inhibitors (e.g., Bempedoic acid), and gene silencing approaches; (4) exploration of HMGCR as a metabolic dependency in solid tumors (e.g., hepatocellular carcinoma, prostate cancer). The next wave of R&D addresses statin-intolerant populations and homozygous familial hypercholesterolemia (HoFH) through these novel modalities.
Key Structural & Functional Insights
HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase) is the rate-limiting enzyme in the mevalonate pathway. The protein contains a sterol-sensing domain (SSD) which is critical for feedback regulation by cholesterol. Mutations in HMGCR are associated with limb-girdle muscular dystrophy type 2R (LGMDR28). Key mutations include p.(?) variants of uncertain significance and likely pathogenic changes affecting hydroxymethylglutaryl-CoA reductase activity. Understanding the structural topology – an ER-membrane-anchored N-terminal domain and a cytosolic catalytic domain – is essential for designing effective inhibitors, degraders, and gene therapy approaches. TarMart provides high-purity catalytic domain proteins and full-length ORF lentiviral particles to support these studies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Next-gen Statins / Allosteric Inhibitors) | Pfizer, Novartis, Major Pharma | Hypercholesterolemia, CVD Prevention, NASH | Enzyme Kinetics & Competition Assays (Need high-purity active HMGCR) |
| Protein Degrader (PROTAC / Molecular Glue) | Emerging Biotech, Academia | Statin-Resistant Hypercholesterolemia, Oncology | Degradation Assay (Need Lentivirus for stable cell lines preserving ER topology) |
| siRNA / Gene Silencing | Alnylam, Arrowhead | Statin-intolerant patients | Knockdown Validation (Need validated siRNA and overexpression controls) |
| Combination Therapy (w/ PCSK9, ACLY, LDLR) | Amgen, Sanofi, Various | Severe dyslipidemia, Refractory Hyperlipidemia | Pathway Analysis (Need PCSK9, ACLY, LDLR proteins and dual-target assays) |
| Gene Therapy | Preclinical Startups | HoFH | Cell Line Construction (Need Lentivirus for stable HMGCR expression) |